Abbott Laboratories (ABT) Stock Analysis

Headquartered in Abbott Park, Illinois, Abbott Laboratories operates across the healthcare sector with its strongest focus on medical devices. Founded in 1888, the company generates revenue across four distinct divisions: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceuticals. It sells generic medications, point-of-care diagnostic testing systems, adult and infant nutrition formulas, and specialized cardiovascular and neuromodulation hardware. Buyers include global hospital networks, clinical laboratories, blood banks, and individual consumers managing chronic illnesses.

Abbott is an established market leader whose primary competitive edge lies in scale and product breadth. Its crown jewel is the FreeStyle Libre continuous glucose monitor, which drove the Diabetes Care segment to 6.8 billion dollars in revenue in 2024. Medtronic, Boston Scientific, and Dexcom give Abbott fierce competition across structural heart, rhythm management, and diabetes sensors. Even with persistent pricing pressure and device iteration cycles from rivals, Abbott’s mix of high-margin devices and staple consumer nutrition provides a cash flow floor that pure-play medtech rivals cannot match.

The business is growing steadily, generating 42.0 billion dollars in total revenue in 2024, up from 40.1 billion dollars in 2023. Medical Devices is the company’s clear growth engine, accounting for 19 billion dollars in 2024 sales behind double-digit gains in electrophysiology and diabetes care. Abbott has fully moved past the drop in pandemic-era rapid testing demand and is actively directing capital into automated insulin delivery partnerships and cardiovascular pipelines. It is one of the most reliable large-cap plays in healthcare, provided it keeps defending its diabetes turf against Dexcom.